Travere Therapeutics TVTX
NASDAQ TVTX
$56.85 -2.03 (-3.45%)
At close: Oct 1, 2026 · 4:00 PM EDT

Travere Therapeutics (TVTX) EBITDA Margin (2014 - 2026)

Updated

Travere Therapeutics' EBITDA Margin came in at 4.83% for Q2 2026, up 3.63 percentage points from 1.19% a year earlier and up 14.03 percentage points from the prior quarter.

Analysis

Travere Therapeutics (TVTX) EBITDA Margin (2014 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Travere Therapeutics reported EBITDA Margin of 3.87%, up 40.43 percentage points year-over-year; for FY2025, it was -0.42%, up 119.77 percentage points from FY2024.

  • EBITDA Margin has increased in each of the last four years, with a five-year change of +76.01 percentage points (FY2020 to FY2025).
  • Going back by year, EBITDA Margin was -120.20% in FY2024 (+120.52 pp), -240.71% in FY2023 (+32.53 pp), -273.25% in FY2022 (+1282.41 pp) and -1555.66% in FY2021 (-1479.22 pp).
  • The five-year range for quarterly EBITDA Margin is -772.26% (Q4 2021) to 24.70% (Q3 2025).
  • Year-over-year, EBITDA Margin has increased for nine consecutive quarters, with an average year-over-year change of +104.34 percentage points over the last eight quarters.
  • The fastest year-over-year change in EBITDA Margin over five years came in Q4 2022 (a gain of 498.25 percentage points), and the weakest in Q4 2021 (a drop of 552.74 percentage points).
  • Business Quant data shows TVTX's EBITDA Margin at -9.20% (Q1 2026), -11.02% (Q4 2025) and 24.70% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 35.95%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 49.01%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 6.02%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 33.11%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 46.01%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -124.26%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 39.10%
10 Travere Therapeutics 5.55 Bn 5.14 Bn 167.41 Mn 4.83%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.83%
Mar 31, 2026 -9.20%
Dec 31, 2025 -11.02%
Sep 30, 2025 24.70%
Jun 30, 2025 1.19%
Mar 31, 2025 -36.55%
Dec 31, 2024 -65.05%
Sep 30, 2024 -71.40%
Jun 30, 2024 -105.99%
Mar 31, 2024 -312.65%
Dec 31, 2023 -188.08%
Sep 30, 2023 -218.65%
Jun 30, 2023 -288.87%
Mar 31, 2023 -293.80%
Dec 31, 2022 -274.00%
Sep 30, 2022 -297.05%
Jun 30, 2022 -245.92%
Mar 31, 2022 -277.16%
Dec 31, 2021 -772.26%
Sep 30, 2021 -34.94%
API Access

Travere Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=TVTX&period=max&api_key=YOUR_API_KEY